Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 47 studies | 57% ± 18% | |
classical monocyte | 26 studies | 40% ± 16% | |
monocyte | 18 studies | 34% ± 19% | |
myeloid cell | 15 studies | 44% ± 20% | |
conventional dendritic cell | 13 studies | 27% ± 8% | |
dendritic cell | 12 studies | 31% ± 14% | |
alveolar macrophage | 8 studies | 57% ± 19% | |
non-classical monocyte | 7 studies | 34% ± 13% | |
mononuclear phagocyte | 6 studies | 49% ± 14% | |
microglial cell | 6 studies | 19% ± 4% | |
intermediate monocyte | 5 studies | 44% ± 13% | |
neutrophil | 3 studies | 24% ± 7% | |
leukocyte | 3 studies | 22% ± 2% | |
tissue-resident macrophage | 3 studies | 65% ± 15% | |
inflammatory macrophage | 3 studies | 59% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 89% | 23991.19 | 515 / 578 | 84% | 42.69 | 970 / 1155 |
breast | 69% | 7758.85 | 317 / 459 | 84% | 28.97 | 944 / 1118 |
adrenal gland | 88% | 13212.74 | 228 / 258 | 50% | 15.68 | 114 / 230 |
bladder | 71% | 6918.33 | 15 / 21 | 56% | 22.05 | 281 / 504 |
intestine | 75% | 7371.15 | 727 / 966 | 51% | 15.58 | 270 / 527 |
ovary | 49% | 3739.80 | 89 / 180 | 67% | 16.26 | 287 / 430 |
stomach | 52% | 4522.48 | 186 / 359 | 60% | 14.47 | 173 / 286 |
pancreas | 30% | 1367.26 | 97 / 328 | 81% | 39.56 | 145 / 178 |
skin | 32% | 1622.25 | 574 / 1809 | 78% | 34.54 | 368 / 472 |
thymus | 42% | 2525.13 | 274 / 653 | 66% | 14.08 | 400 / 605 |
uterus | 51% | 3439.68 | 87 / 170 | 55% | 15.05 | 252 / 459 |
esophagus | 54% | 5416.12 | 778 / 1445 | 49% | 9.59 | 90 / 183 |
kidney | 26% | 3329.51 | 23 / 89 | 77% | 40.69 | 691 / 901 |
spleen | 93% | 32565.56 | 224 / 241 | 0% | 0 | 0 / 0 |
adipose | 92% | 21681.15 | 1113 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 120.17 | 25 / 29 |
liver | 30% | 2025.55 | 68 / 226 | 54% | 10.92 | 218 / 406 |
blood vessel | 71% | 10506.76 | 951 / 1335 | 0% | 0 | 0 / 0 |
prostate | 36% | 1965.96 | 89 / 245 | 33% | 4.99 | 167 / 502 |
brain | 6% | 308.25 | 160 / 2642 | 61% | 51.03 | 430 / 705 |
tonsil | 0% | 0 | 0 / 0 | 64% | 16.32 | 29 / 45 |
peripheral blood | 61% | 15967.24 | 567 / 929 | 0% | 0 | 0 / 0 |
heart | 50% | 4289.13 | 428 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 4.06 | 20 / 80 |
muscle | 18% | 679.72 | 143 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016192 | Biological process | vesicle-mediated transport |
GO_0006953 | Biological process | acute-phase response |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0097110 | Molecular function | scaffold protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0005044 | Molecular function | scavenger receptor activity |
Gene name | CD163 |
Protein name | Scavenger receptor cysteine-rich type 1 protein M130 (Hemoglobin scavenger receptor) (CD antigen CD163) [Cleaved into: Soluble CD163 (sCD163)] CD163 molecule |
Synonyms | M130 |
Description | FUNCTION: Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.; FUNCTION: After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions. |
Accessions | ENST00000359156.8 [Q86VB7-1] H0YFM0 ENST00000542280.5 ENST00000432237.3 [Q86VB7-3] Q86VB7 ENST00000396620.7 ENST00000541972.5 ENST00000537626.5 H0YGZ7 F5GZZ9 C9JHR8 |